[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data
Summary
We read with interest the systematic review by C Tang and colleagues1 and compliment the authors for their comprehensive primary analysis of six randomised clinical trials (RCTs) comparing metastasis-directed therapy (MDT) with standard of care (SOC) in oligometastatic prostate cancer. However, we identified several important design concerns and methodological limitations that could compromise the validity and inter…
We read with interest the systematic review by C Tang and colleagues1 and compliment the authors for their comprehensive primary analysis of six randomised clinical trials (RCTs) comparing metastasis-directed therapy (MDT) with standard of care (SOC) in oligometastatic prostate cancer. However, we identified several important design concerns and methodological limitations that could compromise the validity and interpretation of the findings.